Phillip Parente
Overview
Explore the profile of Phillip Parente including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
832
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
41.
Parente P, Ng S, Parnis F, Guminski A, Gurney H
Asia Pac J Clin Oncol
. 2017 May;
13(6):391-399.
PMID: 28488360
Aim: Cabazitaxel is a next generation taxane that has been shown to improve overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease progressed during or after docetaxel-based...
42.
Bowyer S, Prithviraj P, Lorigan P, Larkin J, McArthur G, Atkinson V, et al.
Br J Cancer
. 2017 Mar;
116(8):e15.
PMID: 28324885
No abstract available.
43.
Au L, Turner N, Wong H, Field K, Lee B, Boadle D, et al.
Asia Pac J Clin Oncol
. 2017 Mar;
14(2):e167-e174.
PMID: 28299879
Aim: Current efforts to understand patient management in clinical practice are largely based on clinician surveys with uncertain reliability. The TRACC (Treatment of Recurrent and Advanced Colorectal Cancer) database is...
44.
Lee B, Wong H, Tacey M, Tie J, Wong R, Lee M, et al.
Asia Pac J Clin Oncol
. 2016 Nov;
13(4):314-321.
PMID: 27885818
Background: Debate continues regarding the benefits versus risks of initial resection of the primary tumor in metastatic colorectal cancer (mCRC) patients with an asymptomatic primary tumor. Although the benefit of...
45.
Wong K, Lee M, Davis I, Parente P, McKendrick J, Pezaro C
Asia Pac J Clin Oncol
. 2016 Oct;
13(5):e534-e536.
PMID: 27726296
Posterior reversible encephalopathy syndrome (PRES) has been described in the context of uncontrolled hypertension, eclampsia, renal disease and autoimmune conditions, or in patients treated with chemotherapy or immunosuppressive agents. In...
46.
Wong H, Lee B, Field K, Lomax A, Tacey M, Shapiro J, et al.
Clin Colorectal Cancer
. 2016 Mar;
15(2):e9-e15.
PMID: 26968236
Background: With an ever-increasing focus on personalized medicine, all factors known to affect treatment response need to be considered when defining optimal therapy for individual patients. While the prognostic impact...
47.
Wong H, Lok S, Wong S, Parente P, Rosenthal M
Prostate Int
. 2015 Jul;
3(2):42-6.
PMID: 26157766
Purpose: To evaluate the use of docetaxel in very elderly men with metastatic castration-resistant prostate cancer (mCRPC) treated in routine clinical care. Methods: A retrospective case series of men with...
48.
Parente P, Gurney H, Ng S, Bahre M
Asia Pac J Clin Oncol
. 2015 Apr;
11(3):199-207.
PMID: 25856659
Prostate cancer, and in particular the management options for patients with metastatic castration-resistant prostate cancer (mCRPC), remains an important health issue. The approval of cabazitaxel provides a new treatment option...
49.
Tiu C, Pezaro C, Davis I, Grossmann M, Parente P
Asia Pac J Clin Oncol
. 2015 Apr;
11(2):190-4.
PMID: 25855890
Ipilimumab is a human anti-CTLA-4 monoclonal antibody recently approved for the treatment of advanced melanoma. Stimulation of T-cell activity unmasks antitumor activity, but can cause immune-related adverse events. Autoimmune hypophysitis...
50.
Migrant health in cancer: outcome disparities and the determinant role of migrant-specific variables
Sze M, Butow P, Bell M, Vaccaro L, Dong S, Eisenbruch M, et al.
Oncologist
. 2015 Mar;
20(5):523-31.
PMID: 25802406
Background: Multiethnic societies face challenges in delivering evidence-based culturally competent health care. This study compared health-related quality of life and psychological morbidity in a hospital-based sample of first-generation migrants and...